Meis­sa ob­tains $30M Se­ries A from Morn­ing­side to test syn­thet­ic bi­ol­o­gy ap­proach to 'elu­sive' RSV vac­cines

Morn­ing­side Ven­tures has writ­ten a $30 mil­lion check to fu­el an ear­ly-stage ex­plo­ration of a new kind of res­pi­ra­to­ry syn­cy­tial virus.

Meis­sa Vac­cines has cho­sen a field in which the most high-pro­file re­cent de­vel­op­ment might be the demise of Gates Foun­da­tion-backed No­vaVax, af­ter its can­di­date failed to pro­tect ei­ther in­fants or the el­der­ly from res­pi­ra­to­ry tract in­fec­tions caused by RSV. As­traZeneca has had more luck with an an­ti­body ap­proach, but oth­er dis­ap­point­ments abound.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.